For moderate to severe rheumatoid arthritis (RA) in adult TNFi‑IR patients1

Older woman in a harness, ziplining

Durable
remission
With or
Without MTX2-5

RINVOQ achieved DAS28-CRP<2.6* and
DAS28-CRP≤3.2 (ranked secondary endpoints) at Week 12 or 14, with durable remission and low disease activity rates from 60 to
84 weeks.1,3,5-7

*Does not mean drug-free remission or complete absence of disease activity.
RINVOQ is indicated for TNFi-IR patients.

CRP=C-reactive protein; DAS28=disease activity score 28 joints; IR=intolerance or inadequate response; MTX=methotrexate; TNFi=tumor necrosis factor inhibitor

Clinical Trial Overview
RINVOQ is indicated for TNFi-IR patients

SELECT-BEYOND: Primary endpoint was ACR20 response at Week 12 bDMARD-IR

*P<0.0001 RINVOQ vs Placebo

SELECT-BEYOND (STUDY RA-V):1,6
12-week, randomized, double-blind, placebo-controlled study of 499 adult patients with moderate to severe RA who had an inadequate response or intolerance to bDMARDs. Patients on background csDMARDs were randomized to receive RINVOQ 15 mg once daily (n=164) or placebo (n=169). The primary endpoint was ACR20 response at Week 12.

SELECT-MONOTHERAPY: Primary endpoint was ACR20 response at Week 14 MTX-IR

*P<0.0001 RINVOQ vs MTX

SELECT‑MONOTHERAPY (Study RA-II) Study Design Intro:1,7 
14‑week, randomized, double‑blind, active comparator‑controlled study of 648 adult patients with moderate to severe RA who had an inadequate response to MTX. The primary endpoint was ACR20 response at Week 14.

Remission & LDA RATES With
or Without MTX AT WEEKS 12 AND 141-4,6,7

REMISSION:
(DAS28-CRP<2.6*)

LDA:
(DAS28-CRP≤3.2)

LDA: DAS28-CRP≤3.2 at Weeks 12 or 14 LDA: DAS28-CRP≤3.2 at Weeks 12 or 14 LDA: DAS28-CRP≤3.2 at Weeks 12 or 14

Durable remission
rates with
or without
MTX1-7

SELECT‑BEYOND:
Clinical Remission Data (Up to Week 60)
DAS28-CRP<2.6*

bDMARD-IR patients

42% of RINVOQ + csDMARDs patients achieved remission at 60 weeks

SELECT‑MONOTHERAPY:
Clinical Remission Data (Up to Week 84)
DAS28-CRP<2.6*

MTX-IR patients

46% of RINVOQ patients
achieved remission at 84 weeks

SELECT-MONOTHERAPY: Clinical Remission Data SELECT-MONOTHERAPY: Clinical Remission Data SELECT-MONOTHERAPY: Clinical Remission Data

Durable
LOW DISEASE ACTIVITY
rates With or Without MTX6,7,9,10

SELECT‑BEYOND:
LDA (Up to Week 60)
DAS28-CRP≤3.2

55% of RINVOQ + csDMARDs patients achieved LDA at
60 weeks

SELECT‑MONOTHERAPY:
LDA (Up to Week 84)
DAS28-CRP≤3.2

57% of RINVOQ patients
achieved LDA at 84 weeks

SELECT-MONOTHERAPY: LDA Data SELECT-MONOTHERAPY: LDA Data SELECT-MONOTHERAPY: LDA Data
Join an upcoming educational speaker program webinar

RINVOQ SAFETY DATA

Review the well-studied safety profile of RINVOQ,
including both short- and long-term analyses